Amgen's Q1 earnings call highlighted strong volume growth (14%) across various product lines, particularly Repatha, EVENITY, BLINCYTO, and KYPROLIS.  Management expressed confidence in the resilience of demand for pharmaceuticals despite macroeconomic challenges, with continued investment in R&D and the recently announced acquisition of Horizon Therapeutics.  The call also included guidance increases for 2023 revenue and EPS, suggesting a positive outlook for the short term.
[2]
